

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Jakobovits Aya</u>  (Last) (First) (Middle) C/O ADICET BIO, INC. 500 BOYLSTON STREET, 13TH FLOOR  (Street) BOSTON MA 02116  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Adicet Bio, Inc. [ ACET ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/12/2021	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/12/2021		s <sup>(1)</sup>		5,000	D	\$13.2256 <sup>(2)</sup>	221,807 <sup>(3)</sup>	I	See Footnote <sup>(4)</sup>
Common Stock	05/12/2021		s <sup>(1)</sup>		5,000	D	\$13.2409 <sup>(5)</sup>	221,806 <sup>(3)</sup>	I	See Footnote <sup>(6)</sup>
Common Stock								329,199 <sup>(3)</sup>	I	See Footnote <sup>(7)</sup>
Common Stock								135,799	I	See Footnote <sup>(8)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date					

**Explanation of Responses:**

- These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$12.97 to \$13.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The Reporting Person previously transferred 149,307 shares and 149,306 shares from the trust described in footnote (7) to the trusts described in footnotes (4) and (6), respectively.
- Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$13.05 to \$13.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.
- Shares held in a grantor retained annuity trust ("GRAT") of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits the sole annuitant and current beneficiary.
- Shares held in a GRAT of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits the sole annuitant and current beneficiary.

**Remarks:**

/s/ Nick Harvey, Attorney-in-Fact for Aya Jakobovits 05/14/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.